Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etentamig + lenalidomide
- Development stage
- Phase 2
- Lead developer
- AbbVie
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous (etentamig), Oral (lenalidomide)
01
Overview
**etentamig + lenalidomide** is a combination regimen under investigation for the treatment of multiple myeloma, especially in patients with relapsed or refractory disease. Etentamig (ABBV-383) is a bispecific monoclonal antibody designed as a T-cell engager targeting B-cell maturation antigen (BCMA). It recruits and activates T-cells to induce cytotoxicity specifically in BCMA-expressing malignant plasma cells. Lenalidomide is an oral immunomodulatory small molecule that inhibits the proliferation of malignant cells, enhances immune cell function, and modulates cytokine production. It acts via cereblon-mediated E3 ubiquitin ligase complex, leading to the degradation of transcription factors key to plasma cell survival, and also boosts NK cell activity. The combination is designed to synergistically enhance anti-myeloma activity by simultaneous immune-mediated tumor cell destruction and direct tumor cell killing. This regimen is presently in early-phase clinical trials.
- Other names
- etentamigABBV-383ABBV383ABBV 383lenalidomideRevlimid
02
Targets
BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)CK1α (Casein kinase I alpha)CRBN (Cereblon)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)
Beyond the preview
Go deeper on etentamig + lenalidomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etentamig + lenalidomide.